Cafepharma Today

January 27 2025 - Sage rejects Biogen's $469 million takeover offer, says offer undervalues company
Sage rejects Biogen's $469 million takeover offer, says offer undervalues company
Metsera eyes $289M IPO to fund phase 3 weight loss trial
Biogen, Eisai win nod for monthly Leqembi maintenance amid stagnant sales
Sara Brenner, FDA device official, named agency’s acting head
*please scroll down for all the latest news*

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

*please scroll down for all the latest news*

Current News

submit a press release

Schering Sees 5 New Drug Applications In 2009
NASDAQ.com
Tuesday, November 25, 2008 - 7:37am
tags:
AstraZeneca's Real Concern is Map Pharmaceuticals
Seeking Alpha
Tuesday, November 25, 2008 - 7:34am
tags:
Safety risks higher with Avandia than Actos -study
Reuters
Monday, November 24, 2008 - 6:50pm
tags:
Antigenics Vaccine for Brain Cancer Extends Lives
Bloomberg
Monday, November 24, 2008 - 6:49pm
tags:
14 drugs identified as most urgently needing study for off-label use, Stanford professor says
Stanford School of Medicine
Monday, November 24, 2008 - 4:50pm
tags:
FDA extends Somaxon drug review by 3 months
Yahoo/AP
Monday, November 24, 2008 - 4:49pm
tags:
US FDA panel back Takeda gout drug, wants more data
Reuters
Monday, November 24, 2008 - 4:48pm
tags:
A Bloody Good Deal for Johnson & Johnson
Motley Fool
Monday, November 24, 2008 - 4:02pm
tags:
Schering-Plough touts pipeline over competitors'
Yahoo/AP
Monday, November 24, 2008 - 4:01pm
tags:
Fitch's downgrades Eli Lilly over ImClone debt
Yahoo/AP
Monday, November 24, 2008 - 4:01pm
tags:
J&J Backed Child Psychiatry Institute to Support Risperdal Sales
WSJ Online
Monday, November 24, 2008 - 4:00pm
tags:
Cancer network funded by Bristol-Myers, ImClone
Bizjournals.com
Monday, November 24, 2008 - 4:00pm
tags:
Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
Yahoo
Monday, November 24, 2008 - 10:46am
tags:
Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease
Yahoo
Monday, November 24, 2008 - 10:45am
tags:
More biotech bankruptcies on the horizon
Fierce Biotech
Monday, November 24, 2008 - 10:42am
tags:
Biotech sector funds came out as leaders, says S&P
FT Adviser
Monday, November 24, 2008 - 10:41am
tags:
Medicaid Spent $200 Million on Unapproved Drugs
WSJ Online
Monday, November 24, 2008 - 10:39am
tags:
Vectura may expand beyond inhaled drugs
Guardian, UK
Monday, November 24, 2008 - 10:36am
tags:
How Lucrative Is Bristol-Myers Collaboration With Exelixis?
Seeking Alpha
Monday, November 24, 2008 - 10:28am
tags:
Depomed could get $68M in new license deal
Bizjournals.com
Monday, November 24, 2008 - 10:27am
tags:

Pages

Latest CP Wire Articles

FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies
Sapio Sciences launches new drug discovery platform
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
Why Medical and Pharma Sales Reps Should Start Their Own Senior Care Business

Latest Pharmagather Articles

Attacking Estrogen-Receptor-Positive Breast Cancer
In the Pipeline
New Study Reveals Five Crucial Priorities Shaping The Future of Patient Services
Drug Channels
Killing Cancer Patients (Once the Payments Clear)
In the Pipeline
The Big Three PBMs’ 2025 Formulary Exclusions: Humira, Stelara, Private Labels, and the Shaky Future for Pharmacy Biosimilars
Drug Channels
Clinical Trial Readouts Are A-Comin'
In the Pipeline
The Current Environment
In the Pipeline
Informa Connect's Patient Assistance & Access Programs (PAP)
Drug Channels
2025 Brand Drug Challenges: A GoodRx Perspective
Drug Channels
Snake Antivenoms, Computed
In the Pipeline

Latest Jobs

Pharmaceutical Sales Representative - Associate Territory Manager, Cardiometabolic Health
Tuscaloosa, Alabama
Eli Lilly and Company
Neuroscience Account Manager - Lancaster, PA
Lancaster, Pennsylvania, US
Lundbeck
Neuroscience Account Manager - Lancaster, PA
Lancaster, Pennsylvania, 17602
Lundbeck
Account Executive - Women's Health - W Palm Beach
Salt Lake City, Utah, 84101
Myriad Genetics
Pharmaceutical Sales Rep- Associate Territory Manager- Cardiometabolic Health
Tallahassee, Florida
Eli Lilly and Company
Psychiatry Account Manager - Atlanta East / Augusta, GA
Augusta, Georgia, US
Lundbeck
Sr. Training Manager Learning & Performance- Commercial Sales
Yardley, Pennsylvania, United States
EVERSANA
Psychiatry Account Manager - Billings, MT
Billings, Montana, US
Lundbeck
Neuroscience Account Manager - Indianapolis, IN
Indianapolis, Indiana, US
Lundbeck
Hybrid Pharmaceutical Sales Representative- EST/CST
Kansas City, Kansas, 66101
Amplity Health
more jobs

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.

Do Not Allow Advertisers to Use My Personal information